Who We Are

OnQuality is a targeted cancer supportive care (TCSC) pharmaceutical company dedicated to the development of treatments to address specific side effects of cancer therapies, to improve quality-of-life and outcomes for patients fighting cancer.

BOARD OF DIRECTORS

Jie Luo


Chief Scientific Officer, and co-founder of OnQuality Pharmaceuticals. Jie is also a principal investigator at Shanghai Jiao Tong University. Graduated from Peking University and Washington University in St. Louis, she received translational and clinical research training at MIT and Harvard Medical School.




Shiyi Zhang


Shiyi Zhang is the founder of OnQuality Pharmaceuticals. He is also a principal investigator at Shanghai Jiao Tong University. Graduated from Peking University and Washington University in St. Louis, he received translational research training at MIT, and helped to build a biotech startup in Cambridge.




Michael McCullar


Michael McCullar is the Chief Executive Officer of OnQuality Pharmaceuticals. He has more than 20 years of pharmaceutical experience in strategic planning and development, drug discovery and operation, business development and commercial operation. Previously he served as Chief Operating Officer at Tolero Pharmaceuticals, where he oversaw drug discovery and development activities as well as corporate development, and commercial planning. He played a major role in the acquisition of Tolero by Sumitomo Dainippon Pharma for $780M ($200M upfront). Prior to joining Tolero Pharmaceuticals, he held multiple roles at Astex Pharmaceuticals including Senior Vice President of Business Development where he was involved in the acquisition of Astex Pharmaceuticals by Otsuka for $886M in cash. In addition, he served as Vice President of Development and Operations and led the FDA approval of Dacogen for the treatment of MDS, while at SuperGen, Inc. Dr. McCullar earned a PhD from the University of California and an MBA from the W.P. Carey School of Business, Arizona State University.




Hong Tang


Chief Medical Officer, and co-founder of OnQuality Pharmaceuticals. Hong is a Board-certified physician with more than 15 years’ experience in both drug development and medical affairs, and conducted all phases of clinical trials. She served as VP, Executive Medical Director, Medical Director, and Medical Officer in Dendreon, Juno, Astellas, BMS and NIH.




Eric Yu


Partner, focusing on the investment opportunities in healthcare in Matrix Partners China. Prior to joining Matrix Partners China in 2014, Eric was responsible for healthcare investment at Fidelity Growth Partners China; served the Deputy General Manager at the Northeastern Office of Shenzhen Capital Group; and worked at UBS Investment Bank's Global Healthcare Group and McKinsey's New York Office. Eric also worked as a researcher on bioinformatics and structure-based drug design at Yale and Columbia University, respectively.




Kai Liu


(Bio coming soon!)





SCIENTIFIC & CLINICAL ADVISORS

Milan J. Anadkat, MD


Dr. Milan Anadkat is a Professor of Dermatology at Washington University School of Medicine. He is currently the Residency Program Director and Director of Clinical Trials for the Division of Dermatology. His clinical focus is in the area of complex medical dermatology, with a unique interest in oncodermatology. He has published widely on topics such as dermatologic therapeutics, graft-versus-host disease, and chemotherapy-induced adverse reactions. He has also been invited to deliver over 80 lectures on these topics locally, regionally, nationally, and internationally. Dr. Anadkat is a member of the American Academy of Dermatology, Medical Dermatology Society, American Professors of Dermatology, Society of Investigative Dermatology, and Multinational Association of Supportive Care in Cancer.




Mario E. Lacouture, MD


Dr. Lacouture is a Professor of Dermatology and the Director of the Oncodermatology Program at the Memorial Sloan Kettering Cancer Center. He is a board-certified dermatologist with special interest in dermatologic conditions that result from cancer treatments. His clinical career has been focused on the recognition and management of side effects affecting the skin, hair, and nails of cancer patients and survivors. He is also the Co-chair of the Skin Toxicity Study Group of the Multinational Association of Supportive Care in Cancer (MASCC), an international organization devoted to the understanding of side effects in cancer patients. Dr. Lacouture founded the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary effort comprising patient care, education, and research. He has published extensively, and is the author of Dr Lacouture’s Skin Care Guide for People Living With Cancer and Dermatologic Principles and Practice in Oncology.




Charles L. Loprinzi, MD


Dr. Loprinzi is a medical oncologist with over 25 years of experience. His primary research interest relates to symptom control clinical trials — trials devoted to the treatment, prevention, or better understanding of untoward symptoms that are related to cancer, cancer treatment, or both. Dr. Loprinzi has demonstrated expertise in clinical trial design, and has participated in over 100 clinical trials. He has received significant recognition of his contributions to the field of oncology, including the Komen Foundation Brinker Award in 2002, the 2005 Komen Foundation Professor of Survivorship Award, the 2006 Clinical Research Award from the Association of Community Cancer Centers, and the 2006 Vasomotor Symptoms Research Award from the North American Menopausal Society.




Anisha B. Patel, MD


Dr. Patel is an associate professor of dermatology at the UT MD Anderson Cancer Center and is a board-certified dermatologist and dermatopathologist. One focus of Dr. Patel’s research is in identifying and finding treatments for skin-related adverse events arising from cancer therapy. She believes that by identifying the causes of such events and finding ways to treat them, patients can remain on effective cancer therapies longer and enjoy improved quality of life during their therapy.




Nicholas J. Vogelzang, MD, FASCO, FACP


Dr. Vogelzang is a clinical professor of medicine at the University of Nevada School of Medicine. He is a renowned medical oncologist and cancer researcher. He has authored and co-authored numerous book chapters, abstracts, and peer-reviewed articles. He is the associate chair of the Genitourinary (GU) Committee for US Oncology Research and Vice Chair of GU Committee SWOG, a worldwide network of researchers that design and conduct cancer clinical trials. Dr. Vogelzang has received numerous nationally recognized awards as a physician and researcher, and has helped to advise and pioneer clinical development of many approved therapies.





RESEARCH & MANAGEMENT

Juegang Ju, Sr. Director of Clinical Development


Graduated from Shanghai Jiao Tong University with more than 9 years’ experience in project management for global trials. He served as Associate Director, Project Manager, Senior CRA and CRA in Quintiles, KunTuo, AstraZeneca, Amgen, Novartis and Pharmacons.




Wenxi Li, MD, PhD, Sr. Director of Pharmacology


Graduated from Shanghai Jiao Tong University with more than 10 years of pharmaceutical preclinical drug discovery experience in Novartis and Wuxi AppTec. In Novartis, she worked on target validation, pharmacology, and biomarker discovery. In WuXi AppTec (Shanghai), she worked as the leader of preclinical pharmacology and IND with experience in preclinical development from PCC to IND for more than ten projects.




Shilan Liu, PhD, Sr. Director of Medicinal Chemistry


More than 15 years of experience in R&D of new drugs of antiviral, anti-tumor, immuno-oncology, autoimmunity and central nervous system. He has extensive experience, including project evaluation, compound design (hit to lead & lead optimization) and IND management. He participated in the research and development of the acala and brutinib at WuXi AppTec. He led more than five R&D projects independently, with one of them was about to start clinical research (phase I), and two received clinical approvals.




Wenjie Liu, Director of Finance


Graduated from Shanghai University of International Business and Economics. He has more than 10 years of experience in finance and auditing. He served as Manager or Director of Finance at multiple international companies such as Deloitte, eHiCar Services, Domino’s Pizza, etc. He was also involved in disparate aspects of the fundraising process and US GAAP IPO with in-depth experience in due-diligence, fund raising, IPO and business-related tax matters.




Jie Luo, Chief Scientific Officer


Chief Scientific Officer, and co-founder of OnQuality Pharmaceuticals. Jie is also a principal investigator at Shanghai Jiao Tong University. Graduated from Peking University and Washington University in St. Louis, she received translational and clinical research training at MIT and Harvard Medical School.




Michael McCullar, Chief Executive Officer


Michael McCullar is the Chief Executive Officer of OnQuality Pharmaceuticals. He has more than 20 years of pharmaceutical experience in strategic planning and development, drug discovery and operation, business development and commercial operation. Previously he served as Chief Operating Officer at Tolero Pharmaceuticals, where he oversaw drug discovery and development activities as well as corporate development, and commercial planning. He played a major role in the acquisition of Tolero by Sumitomo Dainippon Pharma for $780M ($200M upfront). Prior to joining Tolero Pharmaceuticals, he held multiple roles at Astex Pharmaceuticals including Senior Vice President of Business Development where he was involved in the acquisition of Astex Pharmaceuticals by Otsuka for $886M in cash. In addition, he served as Vice President of Development and Operations and led the FDA approval of Dacogen for the treatment of MDS, while at SuperGen, Inc. Dr. McCullar earned a PhD from the University of California and an MBA from the W.P. Carey School of Business, Arizona State University.




Hong Tang, Chief Medical Officer


Chief Medical Officer, and co-founder of OnQuality Pharmaceuticals. Hong is a Board-certified physician with more than 14 years’ experience in both drug development and medical affairs, and conducted all phases of clinical trials. She served as VP, Executive Medical Director, Medical Director, and Medical Officer in Dendreon, Juno, Astellas, BMS and NIH.




Robert Tyler, PhD, Sr. Medical Director


He currenlty has 19 years of experience in clinical development and medical affairs as Director of Research at Atrix laboratories and Janssen and Senior Medical Director at Dendreon and Kiadis. Before entering pharmaceutical industry, he had received Doctorate in Physiology from Colorado State University in cardiovascular studies, followed by NIH and American Heart Association post-doctoral fellowships at the University of Colorado Health Sciences Center, and subsequently was appointed as an Assistant Professor at the University of Colorado Denver.




Mark Webb, PhD, Clinical Research Manager


Graduated from Brigham Young University and University of Cincinnati, PhD of immunology with more than 6 years’ experience in all phases of clinical trials in PRA and Medpace.




Jiahu Wu, Sr. Director of Chemistry, Manufacturing and Control


Graduated from China Pharmaceutical University with more than 20 years of experience in new drug R&D, and registration. He participated and led the R&D of 20 generics and close to 60 new drug formulations. He worked at BioStar Biotechnology Co., Ltd., Shanghai Allist Pharmaceuticals Inc., Shanghai ChemPartner Co., Ltd., Shanghai Medicilon Inc., WuXi AppTec (Shanghai), DDSU, fully responsible for formulation and CMC.




Shiyi Zhang, Founder


Shiyi Zhang is the founder of OnQuality Pharmaceuticals. He is also a principal investigator at Shanghai Jiao Tong University. Graduated from Peking University and Washington University in St. Louis, he received translational research training at MIT, and helped to build a biotech startup in Cambridge.